Our findings from both cell line and patient datasets suggest that FSP1 plays a key role in mediating ferroptosis resistance related to NRF2, highlighting the potential of FSP1 as a promising therapeutic target for the treatment of ferroptosis-resistant cancers. The gene discussed is AIFM2; the disease is cancer.